|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.06 AUD | +1.11% |
|
+1.41% | -19.26% |
| Market Cap | 507M 355M 312M 290M 266M 500M 34.16B 3.44B 1.34B 16.8B 1.33B 1.3B 58.07B | P/E 2026 * |
14.2x | P/E 2027 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise Value | 255M 178M 156M 145M 133M 251M 17.15B 1.73B 675M 8.43B 669M 654M 29.15B | EV / Sales 2026 * |
2.57x | EV / Sales 2027 * | 2.13x |
| Free-Float |
83.79% | Yield 2026 * |
0.61% | Yield 2027 * | 0.8% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +1.11% | ||
| 1 week | +1.41% | ||
| Current month | -2.14% | ||
| 1 month | +0.10% | ||
| 3 months | +11.28% | ||
| 6 months | -17.41% | ||
| Current year | -19.26% |
| 1 week | 9.75 |  | 10.42 |
| 1 month | 9.72 | | 10.74 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.75 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Guy van Dievoet
BRD | Director/Board Member | - | 06/09/2024 |
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 3/10/24 | Buy | Director | 8,333 | 0.0166% | ||
| 27/11/23 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 27/11/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.11% | +1.41% | -15.39% | -45.39% | 355M | |
| +0.63% | -3.06% | +16.50% | -10.12% | 66.74B | |
| +1.23% | +2.80% | +38.09% | +200.66% | 53.32B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 48.12B | |
| -1.32% | -7.38% | -57.37% | -56.96% | 38.25B | |
| +0.78% | -1.84% | +53.73% | -25.20% | 29.85B | |
| +0.84% | +0.36% | +67.62% | +84.46% | 23.51B | |
| -5.17% | -12.54% | +58.33% | -55.63% | 21.45B | |
| -1.21% | +1.12% | +0.90% | +164.17% | 19.97B | |
| +1.31% | +3.24% | +81.47% | +157.97% | 16.47B | |
| Average | +0.83% | -0.34% | +29.57% | +46.58% | 31.8B | |
| Weighted average by Cap. | +1.48% | +0.11% | +29.02% | +51.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.16M 69.34M 60.9M 56.64M 51.97M 97.66M 6.68B 673M 263M 3.28B 260M 255M 11.35B | 105M 73.27M 64.35M 59.84M 54.91M 103M 7.06B 711M 278M 3.47B 275M 269M 11.99B |
| Net income | 35.75M 25M 21.96M 20.42M 18.74M 35.21M 2.41B 242M 94.74M 1.18B 93.85M 91.83M 4.09B | 37.77M 26.41M 23.2M 21.57M 19.8M 37.19M 2.54B 256M 100M 1.25B 99.14M 97.01M 4.32B |
| Net Debt | -253M -177M -155M -144M -132M -249M -17.01B -1.71B -669M -8.36B -663M -649M -28.92B | -285M -199M -175M -163M -149M -280M -19.16B -1.93B -754M -9.42B -747M -731M -32.57B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | A$10.06 | +1.11% | 77,255 |
| 23/07/26 | A$9.950 | +0.71% | 74,171 |
| 22/07/26 | A$9.880 | -1.69% | 84,373 |
| 21/07/26 | A$10.05 | -1.86% | 152,029 |
| 20/07/26 | A$10.24 | +3.23% | 211,352 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
